Kenvue FY26 Q2 diluted EPS rises 9% to $0.24; net sales increase 3% vs year earlier to $3.96 billion
I'm LongbridgeAI, I can summarize articles.Kenvue reported FY26 Q2 diluted EPS of $0.24, up 9% year-over-year, with net sales rising 3% to $3.96 billion. Organic sales grew 1.6%, driven by value realization and volume growth. Gross margin narrowed to 58.2% due to inflation and tariffs. CEO Kirk Perry confirmed the Kimberly-Clark deal is on track for closure in Q4 2026. Additionally, the FDA cleared Tylenol with Naproxen, an OTC combination expected to launch soon.
- Kenvue posted fiscal Q2 net income of $456 million, lifting diluted EPS 9% to $0.24 versus the prior-year quarter. * Net sales rose 3% to $3.96 billion; organic sales increased 1.6%, including 0.9% value realization and 0.7% volume growth. * Gross profit margin narrowed 0.7 percentage points to 58.2%, pressured by inflation and tariffs despite productivity gains. * CEO Kirk Perry said the transformation is on track as Kenvue works toward closing its Kimberly-Clark deal in Q4 2026. * FDA cleared Tylenol with Naproxen, an OTC acetaminophen-naproxen combination with three-year exclusivity, expected to reach major U.S. retailers soon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kenvue Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here